Table 3 outlines key considerations before starting GLP-1-based therapy and are in alignment with Canadian Adult Obesity Clinical Practice 2020 and DNSG/EASD 2023 recommendations [51,107]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.